INCELL is developing an oral vaccine business utilizing its proprietary platform technology for stimulating mucosal immunity. INCELL has new clinical products in the pipeline, primarily in the areas of bioterrorism and defense; cell and passive immunotherapy; antibodies, nutritional therapy and supplement products; bioengineering with cell, gene and tissue-based therapeutics; infectious disease; and pre-clinical testing. Diagnostic devices (e.g., for viruses), vaccine therapies (i.e., an oral smallpox vaccine), immunotherapy test kits, gene therapies against cancer and several other products are in the pipeline.